No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache

Abstract Recent studies have indicated that long-term neurological sequelae after COVID-19 are not accompanied by an increase of canonical biomarkers of central nervous system injury in blood, but subgroup stratifications are lacking. This is a particular concern in chronic headache, which can be a...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Laura de Boni [verfasserIn] Alexandru Odainic [verfasserIn] Natalie Gancarczyk [verfasserIn] Luisa Kaluza [verfasserIn] Christian P. Strassburg [verfasserIn] Xenia A. K. Kersting [verfasserIn] Joseph M. Johnson [verfasserIn] Ullrich Wüllner [verfasserIn] Susanne V. Schmidt [verfasserIn] Jacob Nattermann [verfasserIn] Gabor C. Petzold [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2022

Schlagwörter:	Post-acute sequelae of SARS-CoV-2 infection Post-COVID-19 Headache NfL GFAP Biomarkers

Übergeordnetes Werk:	In: Neurological Research and Practice - BMC, 2019, 4(2022), 1, Seite 7
Übergeordnetes Werk:	volume:4 ; year:2022 ; number:1 ; pages:7

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1186/s42466-022-00217-5

Katalog-ID:	DOAJ027378985

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ027378985
003	DE-627
005	20230502100627.0
007	cr uuu---uuuuu
008	230226s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1186/s42466-022-00217-5 \|2 doi
035			\|a (DE-627)DOAJ027378985
035			\|a (DE-599)DOAJ327e6e4c09b34600864468cf80edde8e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC321-571
050		0	\|a RC346-429
100	0		\|a Laura de Boni \|e verfasserin \|4 aut
245	1	0	\|a No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Abstract Recent studies have indicated that long-term neurological sequelae after COVID-19 are not accompanied by an increase of canonical biomarkers of central nervous system injury in blood, but subgroup stratifications are lacking. This is a particular concern in chronic headache, which can be a leading symptom of Post-COVID diseases associated with neuronal damage such as vasculitis or autoimmune encephalitis. We here compared patients with mild Post-COVID-19 syndrome and persistent headache (persistent Post-COVID-19 headache) lasting longer than 12 weeks after the initial serological diagnosis, to patients with mild and severe COVID-19 and COVID-19-negative controls. Levels of neurofilament light chain and glial fibrillary astrocytic protein, i.e. markers of neuronal damage and reactive astrogliosis, were lower in blood from patients with persistent Post-COVID-19 headache compared to patients with severe COVID-19. Hence, our pilot serological study indicates that long-term Post-COVID-19 headache may not be a sign of underlying neuronal damage or neuroinflammation.
650		4	\|a Post-acute sequelae of SARS-CoV-2 infection
650		4	\|a Post-COVID-19
650		4	\|a Headache
650		4	\|a NfL
650		4	\|a GFAP
650		4	\|a Biomarkers
653		0	\|a Neurosciences. Biological psychiatry. Neuropsychiatry
653		0	\|a Neurology. Diseases of the nervous system
700	0		\|a Alexandru Odainic \|e verfasserin \|4 aut
700	0		\|a Natalie Gancarczyk \|e verfasserin \|4 aut
700	0		\|a Luisa Kaluza \|e verfasserin \|4 aut
700	0		\|a Christian P. Strassburg \|e verfasserin \|4 aut
700	0		\|a Xenia A. K. Kersting \|e verfasserin \|4 aut
700	0		\|a Joseph M. Johnson \|e verfasserin \|4 aut
700	0		\|a Ullrich Wüllner \|e verfasserin \|4 aut
700	0		\|a Susanne V. Schmidt \|e verfasserin \|4 aut
700	0		\|a Jacob Nattermann \|e verfasserin \|4 aut
700	0		\|a Gabor C. Petzold \|e verfasserin \|4 aut
773	0	8	\|i In \|t Neurological Research and Practice \|d BMC, 2019 \|g 4(2022), 1, Seite 7 \|w (DE-627)1038162947 \|x 25243489 \|7 nnns
773	1	8	\|g volume:4 \|g year:2022 \|g number:1 \|g pages:7
856	4	0	\|u https://doi.org/10.1186/s42466-022-00217-5 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/327e6e4c09b34600864468cf80edde8e \|z kostenfrei
856	4	0	\|u https://doi.org/10.1186/s42466-022-00217-5 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2524-3489 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 4 \|j 2022 \|e 1 \|h 7

Indexfelder

author_variant	l d b ldb a o ao n g ng l k lk c p s cps x a k k xakk j m j jmj u w uw s v s svs j n jn g c p gcp
matchkey_str	article:25243489:2022----::oeooiaeiecfrernlaaerecieloiinuooi1ptetw
hierarchy_sort_str	2022
callnumber-subject-code	RC
publishDate	2022
allfields	10.1186/s42466-022-00217-5 doi (DE-627)DOAJ027378985 (DE-599)DOAJ327e6e4c09b34600864468cf80edde8e DE-627 ger DE-627 rakwb eng RC321-571 RC346-429 Laura de Boni verfasserin aut No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Recent studies have indicated that long-term neurological sequelae after COVID-19 are not accompanied by an increase of canonical biomarkers of central nervous system injury in blood, but subgroup stratifications are lacking. This is a particular concern in chronic headache, which can be a leading symptom of Post-COVID diseases associated with neuronal damage such as vasculitis or autoimmune encephalitis. We here compared patients with mild Post-COVID-19 syndrome and persistent headache (persistent Post-COVID-19 headache) lasting longer than 12 weeks after the initial serological diagnosis, to patients with mild and severe COVID-19 and COVID-19-negative controls. Levels of neurofilament light chain and glial fibrillary astrocytic protein, i.e. markers of neuronal damage and reactive astrogliosis, were lower in blood from patients with persistent Post-COVID-19 headache compared to patients with severe COVID-19. Hence, our pilot serological study indicates that long-term Post-COVID-19 headache may not be a sign of underlying neuronal damage or neuroinflammation. Post-acute sequelae of SARS-CoV-2 infection Post-COVID-19 Headache NfL GFAP Biomarkers Neurosciences. Biological psychiatry. Neuropsychiatry Neurology. Diseases of the nervous system Alexandru Odainic verfasserin aut Natalie Gancarczyk verfasserin aut Luisa Kaluza verfasserin aut Christian P. Strassburg verfasserin aut Xenia A. K. Kersting verfasserin aut Joseph M. Johnson verfasserin aut Ullrich Wüllner verfasserin aut Susanne V. Schmidt verfasserin aut Jacob Nattermann verfasserin aut Gabor C. Petzold verfasserin aut In Neurological Research and Practice BMC, 2019 4(2022), 1, Seite 7 (DE-627)1038162947 25243489 nnns volume:4 year:2022 number:1 pages:7 https://doi.org/10.1186/s42466-022-00217-5 kostenfrei https://doaj.org/article/327e6e4c09b34600864468cf80edde8e kostenfrei https://doi.org/10.1186/s42466-022-00217-5 kostenfrei https://doaj.org/toc/2524-3489 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2022 1 7
spelling	10.1186/s42466-022-00217-5 doi (DE-627)DOAJ027378985 (DE-599)DOAJ327e6e4c09b34600864468cf80edde8e DE-627 ger DE-627 rakwb eng RC321-571 RC346-429 Laura de Boni verfasserin aut No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Recent studies have indicated that long-term neurological sequelae after COVID-19 are not accompanied by an increase of canonical biomarkers of central nervous system injury in blood, but subgroup stratifications are lacking. This is a particular concern in chronic headache, which can be a leading symptom of Post-COVID diseases associated with neuronal damage such as vasculitis or autoimmune encephalitis. We here compared patients with mild Post-COVID-19 syndrome and persistent headache (persistent Post-COVID-19 headache) lasting longer than 12 weeks after the initial serological diagnosis, to patients with mild and severe COVID-19 and COVID-19-negative controls. Levels of neurofilament light chain and glial fibrillary astrocytic protein, i.e. markers of neuronal damage and reactive astrogliosis, were lower in blood from patients with persistent Post-COVID-19 headache compared to patients with severe COVID-19. Hence, our pilot serological study indicates that long-term Post-COVID-19 headache may not be a sign of underlying neuronal damage or neuroinflammation. Post-acute sequelae of SARS-CoV-2 infection Post-COVID-19 Headache NfL GFAP Biomarkers Neurosciences. Biological psychiatry. Neuropsychiatry Neurology. Diseases of the nervous system Alexandru Odainic verfasserin aut Natalie Gancarczyk verfasserin aut Luisa Kaluza verfasserin aut Christian P. Strassburg verfasserin aut Xenia A. K. Kersting verfasserin aut Joseph M. Johnson verfasserin aut Ullrich Wüllner verfasserin aut Susanne V. Schmidt verfasserin aut Jacob Nattermann verfasserin aut Gabor C. Petzold verfasserin aut In Neurological Research and Practice BMC, 2019 4(2022), 1, Seite 7 (DE-627)1038162947 25243489 nnns volume:4 year:2022 number:1 pages:7 https://doi.org/10.1186/s42466-022-00217-5 kostenfrei https://doaj.org/article/327e6e4c09b34600864468cf80edde8e kostenfrei https://doi.org/10.1186/s42466-022-00217-5 kostenfrei https://doaj.org/toc/2524-3489 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2022 1 7
allfields_unstemmed	10.1186/s42466-022-00217-5 doi (DE-627)DOAJ027378985 (DE-599)DOAJ327e6e4c09b34600864468cf80edde8e DE-627 ger DE-627 rakwb eng RC321-571 RC346-429 Laura de Boni verfasserin aut No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Recent studies have indicated that long-term neurological sequelae after COVID-19 are not accompanied by an increase of canonical biomarkers of central nervous system injury in blood, but subgroup stratifications are lacking. This is a particular concern in chronic headache, which can be a leading symptom of Post-COVID diseases associated with neuronal damage such as vasculitis or autoimmune encephalitis. We here compared patients with mild Post-COVID-19 syndrome and persistent headache (persistent Post-COVID-19 headache) lasting longer than 12 weeks after the initial serological diagnosis, to patients with mild and severe COVID-19 and COVID-19-negative controls. Levels of neurofilament light chain and glial fibrillary astrocytic protein, i.e. markers of neuronal damage and reactive astrogliosis, were lower in blood from patients with persistent Post-COVID-19 headache compared to patients with severe COVID-19. Hence, our pilot serological study indicates that long-term Post-COVID-19 headache may not be a sign of underlying neuronal damage or neuroinflammation. Post-acute sequelae of SARS-CoV-2 infection Post-COVID-19 Headache NfL GFAP Biomarkers Neurosciences. Biological psychiatry. Neuropsychiatry Neurology. Diseases of the nervous system Alexandru Odainic verfasserin aut Natalie Gancarczyk verfasserin aut Luisa Kaluza verfasserin aut Christian P. Strassburg verfasserin aut Xenia A. K. Kersting verfasserin aut Joseph M. Johnson verfasserin aut Ullrich Wüllner verfasserin aut Susanne V. Schmidt verfasserin aut Jacob Nattermann verfasserin aut Gabor C. Petzold verfasserin aut In Neurological Research and Practice BMC, 2019 4(2022), 1, Seite 7 (DE-627)1038162947 25243489 nnns volume:4 year:2022 number:1 pages:7 https://doi.org/10.1186/s42466-022-00217-5 kostenfrei https://doaj.org/article/327e6e4c09b34600864468cf80edde8e kostenfrei https://doi.org/10.1186/s42466-022-00217-5 kostenfrei https://doaj.org/toc/2524-3489 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2022 1 7
allfieldsGer	10.1186/s42466-022-00217-5 doi (DE-627)DOAJ027378985 (DE-599)DOAJ327e6e4c09b34600864468cf80edde8e DE-627 ger DE-627 rakwb eng RC321-571 RC346-429 Laura de Boni verfasserin aut No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Recent studies have indicated that long-term neurological sequelae after COVID-19 are not accompanied by an increase of canonical biomarkers of central nervous system injury in blood, but subgroup stratifications are lacking. This is a particular concern in chronic headache, which can be a leading symptom of Post-COVID diseases associated with neuronal damage such as vasculitis or autoimmune encephalitis. We here compared patients with mild Post-COVID-19 syndrome and persistent headache (persistent Post-COVID-19 headache) lasting longer than 12 weeks after the initial serological diagnosis, to patients with mild and severe COVID-19 and COVID-19-negative controls. Levels of neurofilament light chain and glial fibrillary astrocytic protein, i.e. markers of neuronal damage and reactive astrogliosis, were lower in blood from patients with persistent Post-COVID-19 headache compared to patients with severe COVID-19. Hence, our pilot serological study indicates that long-term Post-COVID-19 headache may not be a sign of underlying neuronal damage or neuroinflammation. Post-acute sequelae of SARS-CoV-2 infection Post-COVID-19 Headache NfL GFAP Biomarkers Neurosciences. Biological psychiatry. Neuropsychiatry Neurology. Diseases of the nervous system Alexandru Odainic verfasserin aut Natalie Gancarczyk verfasserin aut Luisa Kaluza verfasserin aut Christian P. Strassburg verfasserin aut Xenia A. K. Kersting verfasserin aut Joseph M. Johnson verfasserin aut Ullrich Wüllner verfasserin aut Susanne V. Schmidt verfasserin aut Jacob Nattermann verfasserin aut Gabor C. Petzold verfasserin aut In Neurological Research and Practice BMC, 2019 4(2022), 1, Seite 7 (DE-627)1038162947 25243489 nnns volume:4 year:2022 number:1 pages:7 https://doi.org/10.1186/s42466-022-00217-5 kostenfrei https://doaj.org/article/327e6e4c09b34600864468cf80edde8e kostenfrei https://doi.org/10.1186/s42466-022-00217-5 kostenfrei https://doaj.org/toc/2524-3489 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2022 1 7
allfieldsSound	10.1186/s42466-022-00217-5 doi (DE-627)DOAJ027378985 (DE-599)DOAJ327e6e4c09b34600864468cf80edde8e DE-627 ger DE-627 rakwb eng RC321-571 RC346-429 Laura de Boni verfasserin aut No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Recent studies have indicated that long-term neurological sequelae after COVID-19 are not accompanied by an increase of canonical biomarkers of central nervous system injury in blood, but subgroup stratifications are lacking. This is a particular concern in chronic headache, which can be a leading symptom of Post-COVID diseases associated with neuronal damage such as vasculitis or autoimmune encephalitis. We here compared patients with mild Post-COVID-19 syndrome and persistent headache (persistent Post-COVID-19 headache) lasting longer than 12 weeks after the initial serological diagnosis, to patients with mild and severe COVID-19 and COVID-19-negative controls. Levels of neurofilament light chain and glial fibrillary astrocytic protein, i.e. markers of neuronal damage and reactive astrogliosis, were lower in blood from patients with persistent Post-COVID-19 headache compared to patients with severe COVID-19. Hence, our pilot serological study indicates that long-term Post-COVID-19 headache may not be a sign of underlying neuronal damage or neuroinflammation. Post-acute sequelae of SARS-CoV-2 infection Post-COVID-19 Headache NfL GFAP Biomarkers Neurosciences. Biological psychiatry. Neuropsychiatry Neurology. Diseases of the nervous system Alexandru Odainic verfasserin aut Natalie Gancarczyk verfasserin aut Luisa Kaluza verfasserin aut Christian P. Strassburg verfasserin aut Xenia A. K. Kersting verfasserin aut Joseph M. Johnson verfasserin aut Ullrich Wüllner verfasserin aut Susanne V. Schmidt verfasserin aut Jacob Nattermann verfasserin aut Gabor C. Petzold verfasserin aut In Neurological Research and Practice BMC, 2019 4(2022), 1, Seite 7 (DE-627)1038162947 25243489 nnns volume:4 year:2022 number:1 pages:7 https://doi.org/10.1186/s42466-022-00217-5 kostenfrei https://doaj.org/article/327e6e4c09b34600864468cf80edde8e kostenfrei https://doi.org/10.1186/s42466-022-00217-5 kostenfrei https://doaj.org/toc/2524-3489 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2022 1 7
language	English
source	In Neurological Research and Practice 4(2022), 1, Seite 7 volume:4 year:2022 number:1 pages:7
sourceStr	In Neurological Research and Practice 4(2022), 1, Seite 7 volume:4 year:2022 number:1 pages:7
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Post-acute sequelae of SARS-CoV-2 infection Post-COVID-19 Headache NfL GFAP Biomarkers Neurosciences. Biological psychiatry. Neuropsychiatry Neurology. Diseases of the nervous system
isfreeaccess_bool	true
container_title	Neurological Research and Practice
authorswithroles_txt_mv	Laura de Boni @@aut@@ Alexandru Odainic @@aut@@ Natalie Gancarczyk @@aut@@ Luisa Kaluza @@aut@@ Christian P. Strassburg @@aut@@ Xenia A. K. Kersting @@aut@@ Joseph M. Johnson @@aut@@ Ullrich Wüllner @@aut@@ Susanne V. Schmidt @@aut@@ Jacob Nattermann @@aut@@ Gabor C. Petzold @@aut@@
publishDateDaySort_date	2022-01-01T00:00:00Z
hierarchy_top_id	1038162947
id	DOAJ027378985
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ027378985</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502100627.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s42466-022-00217-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ027378985</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ327e6e4c09b34600864468cf80edde8e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC321-571</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC346-429</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Laura de Boni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Recent studies have indicated that long-term neurological sequelae after COVID-19 are not accompanied by an increase of canonical biomarkers of central nervous system injury in blood, but subgroup stratifications are lacking. This is a particular concern in chronic headache, which can be a leading symptom of Post-COVID diseases associated with neuronal damage such as vasculitis or autoimmune encephalitis. We here compared patients with mild Post-COVID-19 syndrome and persistent headache (persistent Post-COVID-19 headache) lasting longer than 12 weeks after the initial serological diagnosis, to patients with mild and severe COVID-19 and COVID-19-negative controls. Levels of neurofilament light chain and glial fibrillary astrocytic protein, i.e. markers of neuronal damage and reactive astrogliosis, were lower in blood from patients with persistent Post-COVID-19 headache compared to patients with severe COVID-19. Hence, our pilot serological study indicates that long-term Post-COVID-19 headache may not be a sign of underlying neuronal damage or neuroinflammation.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Post-acute sequelae of SARS-CoV-2 infection</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Post-COVID-19</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Headache</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">NfL</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">GFAP</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biomarkers</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neurosciences. Biological psychiatry. Neuropsychiatry</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neurology. Diseases of the nervous system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alexandru Odainic</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Natalie Gancarczyk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luisa Kaluza</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Christian P. Strassburg</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xenia A. K. Kersting</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Joseph M. Johnson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ullrich Wüllner</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Susanne V. Schmidt</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jacob Nattermann</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gabor C. Petzold</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Neurological Research and Practice</subfield><subfield code="d">BMC, 2019</subfield><subfield code="g">4(2022), 1, Seite 7</subfield><subfield code="w">(DE-627)1038162947</subfield><subfield code="x">25243489</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/s42466-022-00217-5</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/327e6e4c09b34600864468cf80edde8e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/s42466-022-00217-5</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2524-3489</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="h">7</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Laura de Boni
spellingShingle	Laura de Boni misc RC321-571 misc RC346-429 misc Post-acute sequelae of SARS-CoV-2 infection misc Post-COVID-19 misc Headache misc NfL misc GFAP misc Biomarkers misc Neurosciences. Biological psychiatry. Neuropsychiatry misc Neurology. Diseases of the nervous system No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache
authorStr	Laura de Boni
ppnlink_with_tag_str_mv	@@773@@(DE-627)1038162947
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC321-571
illustrated	Not Illustrated
issn	25243489
topic_title	RC321-571 RC346-429 No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache Post-acute sequelae of SARS-CoV-2 infection Post-COVID-19 Headache NfL GFAP Biomarkers
topic	misc RC321-571 misc RC346-429 misc Post-acute sequelae of SARS-CoV-2 infection misc Post-COVID-19 misc Headache misc NfL misc GFAP misc Biomarkers misc Neurosciences. Biological psychiatry. Neuropsychiatry misc Neurology. Diseases of the nervous system
topic_unstemmed	misc RC321-571 misc RC346-429 misc Post-acute sequelae of SARS-CoV-2 infection misc Post-COVID-19 misc Headache misc NfL misc GFAP misc Biomarkers misc Neurosciences. Biological psychiatry. Neuropsychiatry misc Neurology. Diseases of the nervous system
topic_browse	misc RC321-571 misc RC346-429 misc Post-acute sequelae of SARS-CoV-2 infection misc Post-COVID-19 misc Headache misc NfL misc GFAP misc Biomarkers misc Neurosciences. Biological psychiatry. Neuropsychiatry misc Neurology. Diseases of the nervous system
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Neurological Research and Practice
hierarchy_parent_id	1038162947
hierarchy_top_title	Neurological Research and Practice
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1038162947
title	No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache
ctrlnum	(DE-627)DOAJ027378985 (DE-599)DOAJ327e6e4c09b34600864468cf80edde8e
title_full	No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache
author_sort	Laura de Boni
journal	Neurological Research and Practice
journalStr	Neurological Research and Practice
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2022
contenttype_str_mv	txt
container_start_page	7
author_browse	Laura de Boni Alexandru Odainic Natalie Gancarczyk Luisa Kaluza Christian P. Strassburg Xenia A. K. Kersting Joseph M. Johnson Ullrich Wüllner Susanne V. Schmidt Jacob Nattermann Gabor C. Petzold
container_volume	4
class	RC321-571 RC346-429
format_se	Elektronische Aufsätze
author-letter	Laura de Boni
doi_str_mv	10.1186/s42466-022-00217-5
author2-role	verfasserin
title_sort	no serological evidence for neuronal damage or reactive gliosis in neuro-covid-19 patients with long-term persistent headache
callnumber	RC321-571
title_auth	No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache
abstract	Abstract Recent studies have indicated that long-term neurological sequelae after COVID-19 are not accompanied by an increase of canonical biomarkers of central nervous system injury in blood, but subgroup stratifications are lacking. This is a particular concern in chronic headache, which can be a leading symptom of Post-COVID diseases associated with neuronal damage such as vasculitis or autoimmune encephalitis. We here compared patients with mild Post-COVID-19 syndrome and persistent headache (persistent Post-COVID-19 headache) lasting longer than 12 weeks after the initial serological diagnosis, to patients with mild and severe COVID-19 and COVID-19-negative controls. Levels of neurofilament light chain and glial fibrillary astrocytic protein, i.e. markers of neuronal damage and reactive astrogliosis, were lower in blood from patients with persistent Post-COVID-19 headache compared to patients with severe COVID-19. Hence, our pilot serological study indicates that long-term Post-COVID-19 headache may not be a sign of underlying neuronal damage or neuroinflammation.
abstractGer	Abstract Recent studies have indicated that long-term neurological sequelae after COVID-19 are not accompanied by an increase of canonical biomarkers of central nervous system injury in blood, but subgroup stratifications are lacking. This is a particular concern in chronic headache, which can be a leading symptom of Post-COVID diseases associated with neuronal damage such as vasculitis or autoimmune encephalitis. We here compared patients with mild Post-COVID-19 syndrome and persistent headache (persistent Post-COVID-19 headache) lasting longer than 12 weeks after the initial serological diagnosis, to patients with mild and severe COVID-19 and COVID-19-negative controls. Levels of neurofilament light chain and glial fibrillary astrocytic protein, i.e. markers of neuronal damage and reactive astrogliosis, were lower in blood from patients with persistent Post-COVID-19 headache compared to patients with severe COVID-19. Hence, our pilot serological study indicates that long-term Post-COVID-19 headache may not be a sign of underlying neuronal damage or neuroinflammation.
abstract_unstemmed	Abstract Recent studies have indicated that long-term neurological sequelae after COVID-19 are not accompanied by an increase of canonical biomarkers of central nervous system injury in blood, but subgroup stratifications are lacking. This is a particular concern in chronic headache, which can be a leading symptom of Post-COVID diseases associated with neuronal damage such as vasculitis or autoimmune encephalitis. We here compared patients with mild Post-COVID-19 syndrome and persistent headache (persistent Post-COVID-19 headache) lasting longer than 12 weeks after the initial serological diagnosis, to patients with mild and severe COVID-19 and COVID-19-negative controls. Levels of neurofilament light chain and glial fibrillary astrocytic protein, i.e. markers of neuronal damage and reactive astrogliosis, were lower in blood from patients with persistent Post-COVID-19 headache compared to patients with severe COVID-19. Hence, our pilot serological study indicates that long-term Post-COVID-19 headache may not be a sign of underlying neuronal damage or neuroinflammation.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache
url	https://doi.org/10.1186/s42466-022-00217-5 https://doaj.org/article/327e6e4c09b34600864468cf80edde8e https://doaj.org/toc/2524-3489
remote_bool	true
author2	Alexandru Odainic Natalie Gancarczyk Luisa Kaluza Christian P. Strassburg Xenia A. K. Kersting Joseph M. Johnson Ullrich Wüllner Susanne V. Schmidt Jacob Nattermann Gabor C. Petzold
author2Str	Alexandru Odainic Natalie Gancarczyk Luisa Kaluza Christian P. Strassburg Xenia A. K. Kersting Joseph M. Johnson Ullrich Wüllner Susanne V. Schmidt Jacob Nattermann Gabor C. Petzold
ppnlink	1038162947
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1186/s42466-022-00217-5
callnumber-a	RC321-571
up_date	2024-07-04T01:28:05.810Z
_version_	1803609949669949440
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ027378985</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502100627.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s42466-022-00217-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ027378985</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ327e6e4c09b34600864468cf80edde8e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC321-571</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC346-429</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Laura de Boni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Recent studies have indicated that long-term neurological sequelae after COVID-19 are not accompanied by an increase of canonical biomarkers of central nervous system injury in blood, but subgroup stratifications are lacking. This is a particular concern in chronic headache, which can be a leading symptom of Post-COVID diseases associated with neuronal damage such as vasculitis or autoimmune encephalitis. We here compared patients with mild Post-COVID-19 syndrome and persistent headache (persistent Post-COVID-19 headache) lasting longer than 12 weeks after the initial serological diagnosis, to patients with mild and severe COVID-19 and COVID-19-negative controls. Levels of neurofilament light chain and glial fibrillary astrocytic protein, i.e. markers of neuronal damage and reactive astrogliosis, were lower in blood from patients with persistent Post-COVID-19 headache compared to patients with severe COVID-19. Hence, our pilot serological study indicates that long-term Post-COVID-19 headache may not be a sign of underlying neuronal damage or neuroinflammation.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Post-acute sequelae of SARS-CoV-2 infection</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Post-COVID-19</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Headache</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">NfL</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">GFAP</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biomarkers</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neurosciences. Biological psychiatry. Neuropsychiatry</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neurology. Diseases of the nervous system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alexandru Odainic</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Natalie Gancarczyk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luisa Kaluza</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Christian P. Strassburg</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xenia A. K. Kersting</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Joseph M. Johnson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ullrich Wüllner</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Susanne V. Schmidt</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jacob Nattermann</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gabor C. Petzold</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Neurological Research and Practice</subfield><subfield code="d">BMC, 2019</subfield><subfield code="g">4(2022), 1, Seite 7</subfield><subfield code="w">(DE-627)1038162947</subfield><subfield code="x">25243489</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/s42466-022-00217-5</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/327e6e4c09b34600864468cf80edde8e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/s42466-022-00217-5</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2524-3489</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="h">7</subfield></datafield></record></collection>
score	7.400589

Nicht das Richtige dabei?

Schreiben Sie uns!

No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?